Yan Yuyang, Yin Jiarui, Ding Quan, Lu Yan, Gou Shuhua, Xu Xi, Li Yulin
School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Front Oncol. 2025 Jul 16;15:1622359. doi: 10.3389/fonc.2025.1622359. eCollection 2025.
N6-methyladenosine (m6A) modification is a pivotal mechanism in RNA epigenetics, with profound implications for lung cancer (LC) biology. This review synthesizes current knowledge on m6A's multifaceted regulatory networks in non-small cell lung cancer (NSCLC), elucidating its roles in tumor proliferation, apoptosis, invasion, and metastasis. We further explore how m6A governs metabolic reprogramming-including glycolysis and ferroptosis-angiogenesis, and tumor microenvironment (TME) remodeling. Additionally, m6A-mediated modification of non-coding RNAs contributes to LC malignancy, underscoring its potential as a diagnostic and prognostic biomarker. These findings also offer novel strategies to overcome therapeutic resistance, a critical challenge in NSCLC treatment. Despite its promise, clinical translation of m6A-targeted interventions faces hurdles, such as the lack of standardized detection methods, the complexity of m6A-associated regulatory networks, and unresolved crosstalk with other RNA modifications. Future research should prioritize multi-omics approaches to resolve these challenges and advance m6A from mechanistic discovery toward clinical application. By addressing these gaps, m6A modulation may emerge as a transformative avenue in precision oncology.
N6-甲基腺苷（m6A）修饰是RNA表观遗传学中的关键机制，对肺癌（LC）生物学具有深远影响。本综述综合了目前关于m6A在非小细胞肺癌（NSCLC）中多方面调控网络的知识，阐明了其在肿瘤增殖、凋亡、侵袭和转移中的作用。我们进一步探讨了m6A如何调控代谢重编程（包括糖酵解和铁死亡）、血管生成以及肿瘤微环境（TME）重塑。此外，m6A介导的非编码RNA修饰促进了LC的恶性发展，突显了其作为诊断和预后生物标志物的潜力。这些发现还为克服治疗耐药性提供了新策略，这是NSCLC治疗中的一项关键挑战。尽管前景广阔，但针对m6A的干预措施的临床转化面临障碍，如缺乏标准化检测方法、m6A相关调控网络的复杂性以及与其他RNA修饰未解决的相互作用。未来研究应优先采用多组学方法来解决这些挑战，并推动m6A从机制发现走向临床应用。通过填补这些空白，m6A调控可能成为精准肿瘤学中的变革性途径。
